Platelet receptor glycoprotein IIb/IIIa inhibition with eptifibatide in a patient with thrombocytopenia after treatment with abciximab.

J Invasive Cardiol

Health Centers of Excellence, Inc., Adult Cardiology Division, 2727 West Martin Luther King Jr. Blvd., 8th Floor, Tampa, FL 33607, USA.

Published: October 2000

AI Article Synopsis

Article Abstract

Clinical experience suggests that patients treated with the glycoprotein (GP) IIb/IIIa inhibitor abciximab (ReoPro , Eli Lilly and Company, Indianapolis, Indiana) may be at increased risk of thrombocytopenia. This case report details the successful use of the GP IIb/IIIa inhibitor eptifibatide (Integrilin , COR Therapeutics, South San Francisco, California) in a patient who developed acute thrombocytopenia (platelet count: 67,000/mm3) approximately 10 hours after initiation of abciximab therapy. Five hours after abciximab was discontinued, platelet count returned to normal (191,000/mm3) and eptifibatide was started because of persistent electrocardiographic evidence of ischemia. The patient underwent diagnostic catheterization during eptifibatide therapy, which was administered for approximately three days. Four days after the initial course of therapy with eptifibatide was discontinued, percutaneous revascularization with adjunct eptifibatide was performed. During both courses of eptifibatide therapy, platelet counts remained in the normal range (> 100,000/mm3) and no adverse ischemic or bleeding events occurred.

Download full-text PDF

Source

Publication Analysis

Top Keywords

glycoprotein iib/iiia
8
iib/iiia inhibitor
8
platelet count
8
eptifibatide therapy
8
eptifibatide
7
platelet
4
platelet receptor
4
receptor glycoprotein
4
iib/iiia inhibition
4
inhibition eptifibatide
4

Similar Publications

Objective: Current guidelines recommend the use of glycoprotein IIb/IIIa (GpIIb/IIIa) inhibitors in patients with ST-segment elevation myocardial infarction (STEMI) only as a bail-out therapy. However, drug penetration to the jeopardised area may not be achieved due to impeded blood flow and increased microvascular resistance. Aim of our study is to investigate the impact of distal intracoronary GpIIb/IIIa inhibitor agent infusion in STEMI patients.

View Article and Find Full Text PDF

Platelet Reactivity to Zika and Dengue Non-Structural Protein 1 (NS1) Assessed by Flow Cytometry, Atomic Force Microscopy, and Quartz Crystal Microbalance.

Int J Lab Hematol

December 2024

División de Estudios de Posgrado. Facultad de Ciencias Médicas y Biológicas "Dr. Ignacio Chávez", Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Michoacán, Mexico.

Background: Platelets, besides being traditionally associated with hemostasis, have been recently positioned as immune cells. Alterations in platelet number and function have been reported in some viral infections. Zika virus (ZIKV) and Dengue virus (DENV) are arboviruses that encode for a non-structural protein 1 (NS1).

View Article and Find Full Text PDF

Platelet-sparing properties of aprotinin: A scoping review on mechanisms and clinical effects.

Eur J Anaesthesiol

January 2025

From the Department of Cardiovascular Sciences, KU Leuven (LLWV, SR, RVdE), and the Department of Anesthesiology, University Hospital of the KU Leuven, Leuven, Belgium (LLWV, SR, RVdE).

Background: Cardiac surgery involving cardiopulmonary bypass (CPB) is associated with the risk of acquired coagulopathy, including dysregulated fibrinolysis, which can result in life-threatening bleeding complications. Aprotinin, an antifibrinolytic agent, has been recommended for the prevention of these complications. Its effectiveness has been attributed to its ability to nonspecifically inhibit various serine proteases involved in the coagulation and fibrinolysis cascade.

View Article and Find Full Text PDF

Gastrointestinal Bleeding/Angiodysplasia in Patients With Glanzmann Thrombasthenia.

J Med Cases

December 2024

Madinah Hereditary Blood Disorders Centre, Department of Hematology and Oncology, King Salman Bin Abdulaziz Medical City, Madinah, Saudi Arabia.

Article Synopsis
  • * A rare complication of GT is gastrointestinal angiodysplasia (GIAD), which involves abnormal blood vessel formation in the digestive system and has been documented in eight cases.
  • * Treatment options for GIAD include surgical methods, electrocoagulation, and medications, but it has a high chance of recurring, as demonstrated in reported cases of patients with both GT and gastrointestinal bleeding.
View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on identifying risk factors for stent thrombosis (ST) in patients with STEMI who underwent primary PCI, using data from the TOTAL trial involving over 10,000 patients.
  • Out of the participants, 1.54% experienced ST within a year, with factors like prior heart attacks, number of stents, and certain medications influencing risk.
  • The findings suggest that while ST remains a common complication, different predictors exist for ST occurring at different times after the procedure, emphasizing the need for tailored preventive strategies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!